What is it about?
This paper describes for the first time the capacity of non professional Antigen Presenting Cells (APC), such as tumor cells of epithelial origin, to serve as professional APC for their own tumor antigens and, more importantly, to prime naive vergin T cells to become anti-tumor effectors
Featured Image
Why is it important?
This work discloses the possibility of using CIITA-modified tumor cells as a potent vaccine against a wide variety of cancers
Read the Original
This page is a summary of: Tumor Immunology meets…Immunology: Modified cancer cells as professional APC for priming naïve tumor-specific CD4+ T cells, OncoImmunology, July 2017, Taylor & Francis,
DOI: 10.1080/2162402x.2017.1356149.
You can read the full text:
Contributors
The following have contributed to this page
